Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Gross Profit (2016 - 2025)

Immucell (ICCC) has disclosed Gross Profit for 16 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 49.23% year-over-year to $2.4 million, compared with a TTM value of $11.4 million through Sep 2025, up 122.47%, and an annual FY2024 reading of $7.9 million, up 105.23% over the prior year.
  • Gross Profit was $2.4 million for Q3 2025 at Immucell, down from $2.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $3.4 million in Q1 2025 and bottomed at $300775.0 in Q1 2023.
  • Average Gross Profit over 5 years is $2.0 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Gross Profit plummeted 90.31% in 2023, then surged 663.15% in 2024.
  • Year by year, Gross Profit stood at $2.6 million in 2021, then crashed by 61.25% to $992176.0 in 2022, then increased by 27.69% to $1.3 million in 2023, then soared by 123.51% to $2.8 million in 2024, then dropped by 16.55% to $2.4 million in 2025.
  • Business Quant data shows Gross Profit for ICCC at $2.4 million in Q3 2025, $2.8 million in Q2 2025, and $3.4 million in Q1 2025.